Amniotic tissue treatments for chronic diabetic foot ulcers

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical investigation evaluates the safety and efficacy of various amniotic tissue allografts combined with standard care in treating chronic non-healing diabetic foot ulcers. Participants will receive either an amnion/chorion/amnion allograft, an amnion/chorion allograft, or an amnion/amnion allograft, compared to standard care alone over a 12-week treatment period. The study focuses on patients with diabetic foot ulcers that have persisted for more than four weeks and meet specific size and circulation criteria.

Why it matters

Who can join: the full rules

Inclusion Criteria:

Potential subjects are required to meet all of the following criteria for enrollment into the study.

1. At least 18 years old, inclusive.
2. Presence of a DFU, Wagner Grade 1, extending through the dermis provided it is below the medial aspect of the malleolus.
3. The index ulcer (ulcer to be evaluated in the study) will be the largest ulcer if two or more DFUs are present with the same Wagner grade and will be the only one evaluated in the study. If other ulcerations are present on the same foot, they must be more than 2 cm distant from the index ulcer.
4. Index ulcer has been present for greater than 4 weeks prior to SV1 and less than 1 year, as of the date the subject consents for study.
5. Index ulcer is a minimum of 1.0 cm2 and a maximum of 25 cm2 at SV1 and TV1.
6. Within 3 months of SV1, adequate circulation to the affected foot as documented by a dorsal transcutaneous oxygen measurement (TCOM) or a skin perfusion pressure (SPP) measurement of ≥ 30 mmHg, or an Ankle Branchial Index (ABI) between 0.7 and 1.3 using the affected study extremity. As an alternative, arterial Doppler ultrasound can be performed evaluating for biphasic dorsalis pedis and posterior tibial vessels at the level of the ankle or a TBI (Toe Brachial Index) of \> 0.6 is acceptable.
7. The target ulcer has been offloaded for at least 14 days, prior to TV1.
8. Females of childbearing potential must be willing to use acceptable methods of contraception (birth control pills, barriers or abstinence) during the course of the study and undergo pregnancy tests.
9. Subject understands and is willing to participate in the clinical study and can comply with weekly visits.
10. Subjects must have read and signed the IRB approved ICF before screening procedures are performed.

Exclusion Criteria:

Potential subjects meeting any of the following criteria will be excluded from enrollment and subsequent treatment.

1. Index ulcer(s) deemed by the investigator to be caused by a medical condition other than diabetes
2. Index ulcer, in the opinion of the investigator, is suspicious for cancer and should undergo an ulcer biopsy to rule out a carcinoma of the ulcer
3. Index ulcer is infected
4. Subjects with a history of more than two weeks of treatment with immune-suppressants (including systemic corticosteroids \>10mg daily dose), cytotoxic chemotherapy, or application of topical steroids to the ulcer surface within 1-month prior to first SV1, or who receive such medications during the screening period or who are anticipated to require such medications during the course of the study
5. Subjects on any investigational drug(s), Investigational products, or therapeutic device(s) within 30 days preceding SV1
6. History of radiation at the ulcer site (regardless of time since last radiation treatment)
7. Index ulcer has been previously treated or will need to be treated with any prohibited therapies
8. Subjects with a previous diagnosis of HIV or Hepatitis C
9. Presence of any condition(s) which seriously compromises the subject's ability to complete this study or has a known history of poor adherence with medical treatment
10. Osteomyelitis or bone infection of the affected foot as verified by x-ray within 30 days prior to the first screening visit. (In the event of an ambiguous diagnosis, the Principal Investigator will make the final decision)
11. Subject is pregnant or breast-feeding
12. Presence of diabetes with poor metabolic control as documented with an HbA1c \>12.0 within last 90 days
13. Subjects with end stage renal disease as evidenced by a serum creatinine ≥3.0 mg/dL within 6 months of enrollment
14. Presence of acute Charcot Neuroarthropathy to the affected limb
15. Index ulcer that has reduced in area by 30% or more after 14 days of SOC from SV1 to the TV1/Randomization visit

Where it's running

• Limb Preservation Platform Inc
  Fresno, California, United States Recruiting
• Angel City Research
  Los Angeles, California, United States Recruiting
• Clemente Clinical Research
  Los Angeles, California, United States Recruiting
• ILD Research Center
  Vista, California, United States Recruiting
• Clever Medical Research
  Miami, Florida, United States Recruiting
• Foot and Ankle Specialists of the Mid-Atlantic
  Raleigh, North Carolina, United States Recruiting

Study contacts

• Study coordinator: Frank Burrows III, MBA, EMT, BCMAS, CWCA
• Email: FBurrows@tidesmedical.com
• Phone: 888-494-4441

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Combination Bionerv E+ vs Vitamin B Complex in Type 2 Diabetes with DSPN and Foot Ulcers

  In people with type 2 diabetes and diabetic polyneuropathy, this study tests whether adding alpha-lipoic acid and vitamin E to a vitamin B mix helps nerve symptoms and wound healing better than the vitamin B mix alone.

  Recruiting BREGO Life Sciences · Cheras, Kuala Lumpur · NCT07877948

• DiaFootCare: a mobile app to help adults with diabetic foot ulcers manage self-care in Oman

  A mobile app called DiaFootCare will be tested to see if it helps adults with diabetic foot ulcers in Oman take better care of themselves and improve healing compared with usual care.

  Recruiting Oman Ministry of Health · Muscat · NCT07815275

• Wound gel for diabetic foot ulcers compared with standard care

  This study tests whether the investigational VES-0-D wound gel helps heal mild to moderate diabetic foot ulcers better than standard treatment.

  Recruiting Flen Health · Bonheiden, Antwerp and 7 other locations · NCT07783087

• High-Purity Collagen Skin Substitute vs Fish Skin Matrix for Diabetic Foot Ulcers

  This study tests whether a high-purity type-I collagen skin substitute works better than an acellular fish-skin matrix, when added to standard wound care, for healing diabetic foot ulcers.

  Recruiting at 4 sites Adichunchanagiri Institute of Medical Sciences, B G Nagara · Dhaka and 3 other locations · NCT07781917

• L-Carnitine as an add-on for healing diabetic foot ulcers

  This study tests whether taking L-Carnitine helps wound healing in adults with diabetic foot ulcers, alongside standard diabetes and wound care.

  Recruiting Phase 2 Ain Shams University · Cairo, Cairo Governorate and 1 other locations · NCT07768228

• Coordinated primary-care MDT approach for hard-to-heal ulcers

  A group of adults with hard-to-heal diabetic foot ulcers will be randomly assigned to standard care or a coordinated multidisciplinary team to see if the team approach helps ulcers heal better.

  Recruiting Nordsjaellands Hospital · Hillerød · NCT07747896

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.